SERIES A-1 WARRANT VISTAGEN THERAPEUTICS, INC. Warrant To Purchase Common StockWarrant Agreement • August 31st, 2017 • VistaGen Therapeutics, Inc. • Pharmaceutical preparations • New York
VistaGen Therapeutics, Inc., a company organized under the laws of Nevada (the "Company"), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [HOLDER], the registered holder hereof or its permitted assigns (the "Holder"), is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, at any time or times on or after March 7, 2018 (the “Initial Exercisability Date”), but not after 11:59 p.m., New York time, on the Expiration Date, (as defined below), ______________ (_____________)1 fully paid non-assessable shares of Common Stock (as defined below), subject to adjustment as provided herein (the "Warrant Shares"). Except as otherwise defined herein, capitalized terms in this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, this "Warrant"), shall have the meanin
VistaGen Therapeutics, Inc. 1,371,430 Shares of Common Stock Series A1 Warrants to Purchase up to 1,388,931 Shares of Common Stock and Series A2 Warrants to Purchase up to 503,641 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • August 31st, 2017 • VistaGen Therapeutics, Inc. • Pharmaceutical preparations • New York
VistaGen Therapeutics, Inc., a Nevada corporation (the "Company") proposes, subject to the terms and conditions contained herein, to sell to you (the "Underwriter"), an aggregate of (i) 1,371,430 shares (the "Shares") of the Company's common stock, $0.001 par value per share (the "Common Stock"), (ii) Series A1 warrants (the “Series A1 Warrants”) to purchase up to an aggregate of 1,388,931 shares of Common Stock (the “Series A1 Warrant Shares”) and (iii) Series A2 warrants (the “Series A2 Warrants”, and collectively, with the Series A1 Warrants, the “Warrants”) to purchase an aggregate of 503,641 shares of Common Stock (the “Series A2 Warrant Shares,” and collectively, with the Series A1 Warrant Shares, the “Warrant Shares”). Each Share is being sold together with 1.0128 Series A1 Warrants, each whole Series A1 Warrant to purchase one Series A1 Warrant Share, and 0.3672 of a Series A2 Warrant, each Whole Series A2 Warrant to purchase one Series A2 Warrant Share. The Shares, the Warrant
SERIES A-2 WARRANT VISTAGEN THERAPEUTICS, INC. Warrant To Purchase Common StockWarrant Agreement • August 31st, 2017 • VistaGen Therapeutics, Inc. • Pharmaceutical preparations • New York
VistaGen Therapeutics, Inc., a company organized under the laws of Nevada (the "Company"), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [HOLDER], the registered holder hereof or its permitted assigns (the "Holder"), is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, at any time or times on or after the Issuance Date (the “Initial Exercisability Date”), but not after 11:59 p.m., New York time, on the Expiration Date, (as defined below), ______________ (_____________)1 fully paid non-assessable shares of Common Stock (as defined below), subject to adjustment as provided herein (the "Warrant Shares"). Except as otherwise defined herein, capitalized terms in this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, this "Warrant"), shall have the me
